Loyal

Thesis

Loyal has the highest 'toy phase dismissal' score in biotech. 'a pill to make dogs live longer' sounds absurd until you realize the FDA granted Reasonable Expectation of Effectiveness for both LOY-001 (large breed lifespan extension) and LOY-002 (healthspan). Anticipated launch in 2026 subject to FDA manufacturing/safety approval. The mechanism of action (IGF-1 reduction) is well-understood biology with decades of supporting research. The $100B+ pet care TAM provides an enormous market if the drug works as expected. Average dog owners spend increasing amounts on pet healthcare, and a longevity drug would command premium pricing. Critically, the dog longevity thesis is a potential gateway to human longevity applications. The same IGF-1 pathway is implicated in human aging. If LOY-001 works in dogs, it de-risks the biology for human trials. Weakness. Private company, veterinary market is smaller than human pharma, and FDA approval is not guaranteed. The 'toy phase' is extreme. Most investors literally laugh at the pitch, which is exactly the signal the 8-signal framework identifies as bullish.

Catalysts

• +LOY-001 FDA manufacturing/safety approval anticipated 2026
• +FDA Reasonable Expectation of Effectiveness already granted
• +LOY-002 for healthspan extension following behind
• +Potential gateway to human longevity applications via same pathway

Risks

• -Private company with no public investment path
• -FDA final approval not guaranteed despite positive signals
• -Veterinary market smaller than human pharma TAM
• -Dog longevity concept faces extreme toy-phase dismissal

Common questions